Suggested Reading
ACOG Committee on Practice Bulletins—Gynecology: ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 114:1409–1420, 2009.
Barraclough LH, Swindell R, Livsey JE, et al: External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys 71:772–778, 2008.
Boggess JF, Gehrig PA, Cantrell L, et al: A case-control study of robot-assisted type III radical hysterectomy with pelvic node dissection compared with open radical hysterectomy. Am J Obstet Gynecol 199:357.e1–e7, 2008.
Boughanim M, Leboulleux S, Rey A, et al: Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 26:2558–2561, 2008.
Boulet GA, Horvath CA, Berghmans S, et al: Human Papillomavirus in cervical cancer screening: Important role as biomarker. Cancer Epidemiol Biomarkers Prep 17:810–817, 2008.
Cadron I, Van Gorp T, Amant F, et al: Chemotherapy for recurrent cervical cancer. Gynecol Oncol 107:S113–S118, 2007.
Choi CH, Kim TJ, Lee SJ, et al: Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin(Drug information on cisplatin) for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 16:1157–1164, 2006.
Choi HJ, Ju W, Myung SK, Kim Y: Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: Meta-analysis. Cancer Sci 101:1471–1479, 2010.
Chou HH, Chang TC, Yen TC, et al: Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol 24:123–128, 2006.
Diaz JP, Sonoda Y, Leitao NM, et al: Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 111:255–260, 2008.
Eifel PJ, Gershenson DM, Kavanagh JJ, et al: M.D. Anderson Cancer Care Series: Gynecologic Cancer. New York: Springer; 2006.
Einstein MH, Park KJ, Sonoda Y, et al: Radical vaginal versus abdominal trachelectomy for stage IB1 cervcal cancer: A comparison of surgical and pathologic outcomes. Gynecol Oncol 112:73–77, 2009.
Farley JH, Gibson SJ, Monk BJ: American Society of Clinical Oncology 2012 annual meeting update: Summary of selected gynecologic cancer abstracts. Gynecol Oncol 126:319–324, 2012.
Franckena M, Lutgens LC, Koper PC, et al: Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: Results in 378 patients. Int J Radiat Oncol Biol Phys 73:242–250, 2009.
FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927, 2007.
Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943, 2007.
Gibb RK, Martens MG: The Impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 4(1s):S2–S11, 2011.
Grigsby PW, Siegel BA, Dehdashti F, et al: Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome. J Clin Oncol 22:2167–2171, 2004.
Huang EY, Wang CJ, Chen HC, et al: Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 72:834–842, 2008.
Huguet F, Cojocariu OM, Levy P, et al: Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion. Int J Radiat Oncol Biol Phys 72:1508–1515, 2008.
Husain A, Akhurst T, Larson S, et al: A prospective study of the accuracy of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 106:177–180, 2007.
Justino PB, Baroni R, Blasbalg R, et al: Clinical tumor dimensions may be useful to prevent geographic miss in conventional radiotherapy of uterine cervix cancer—A magnetic resonance imaging-based study. Int J Radiat Oncol Biol Phys 74:503–510, 2009.
Kesic V: Management of cervical cancer. Eur J Surg Oncol 32:832–837, 2006.
Keys HM, Bundy BN, Stehman FB, et al: Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343–353, 2003.
Lai CH, Chang CJ, Huang HJ, et al: Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 25:3628–3634, 2007.
Lanciano R, Calkins A, Bundy BN, et al: Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil(Drug information on fluorouracil) in combination with pelvic radiation in advanced cervix cancer: A Gynecologic Oncology Group Study. J Clin Oncol 23:8289–8294, 2005.
Lehman M, Thomas G: Is concurrent chemotherapy and radiotherapy in the new standard of care for locally advanced cervical cancer? Int J Gynecol Cancer 11:87–99, 2011.
Levenback CF: Status of sentinel lymph node biopsy in gynecological cancers. Ann Surg Oncol 15:18–20, 2008.
Lin LL, Mutic S, Low DA, et al: Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys 67:91–96, 2007.
Loft A, Berthelsen AK, Roed H, et al: The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. Gynecol Oncol 106:29–34, 2007.
Long HJ 3rd: Management of metastatic cervical cancer: Review of the literature. J Clin Oncol 25:2966–2974, 2007.
Long HJ 3rd, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan(Drug information on topotecan) in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633, 2005.
Lowe MP, Chamberlain DH, Kamelle SA, et al: A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol 113:191–194, 2009.
Lutgens L, van der Zee J, Pijls-Johannesma M, et al: Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma. Cochrane Database Syst Rev 3:CD006377, 2010.
Maluf FC, Leiser AL, Aghajanian C, et al: Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16:1165–1171, 2006.
Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579–1588, 2007.
Mitchell DG, Snyder B, Coakley F, et al: Early invasive cervical cancer: Tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathological results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 24:5687–5694, 2006.
Monk BJ, Huang HQ, Cella D, et al: Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4617–4625, 2005.
Monk BJ, Sill MW, Burger RA, et al: A phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A GOG study. J Clin Oncol 27:1069–1074, 2009.
Monk BJ, Sill M, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655, 2009.
Odicino F, Pecorelli S, Zigliani L, et al: History of the FIGO cancer staging system. Int J Gynaecol Obstet 101:205–210, 2008.
Pearcey R, Miao Q, Kong W, et al: Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: Results of a population-based cohort study. J Clin Oncol 25:2383–2388, 2007.
Pecorelli S, Zigliani L, Odicino F: Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107–108, 2009.
Potter R, Haie-Meder C, Van Limbergen E, et al: Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78:67–77, 2006.
Rose PG, Ali S, Watkins E, et al: Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:2804–2810, 2007.
Rose PG, Ali S, Whitney CW, et al: Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecol Obstet 117:270–275, 2010.
Rotman M, Sedlis A, Piedmonte MR, et al: A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a Gynecologic Oncology Group Study. Int J Radiat Oncol Biol Phys 65:169–176, 2006.
Saito I, Kitagawa R, Fukuda H, et al: A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 40:90–93, 2010.
Santin DA, Sill MW, McMeekin DS, et al: Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 122:495–500, 2011.
Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147–172, 2012.
Schneider A, Köhler C, Erdemoglu E: Current developments for pelvic exenteration in gynecologic oncology. Curr Opin Obstet Gynecol 21:4–9, 2009.
Stanley M: Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 20:388–394, 2008.
Tierney J: Neoadjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 39:2470–2486, 2003.
U.S. Preventive Services Task Force: Screening for Cervical Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ publication 11-05156-EF-3, March 2012. http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancersum.htm.
Vale C, Tierney JF, Stewart LA, et al; Meta-Analysis Group: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Asystematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–5812, 2008.
Vistad I, Cvancarova M, Fosså SD, Kristensen GB: Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 71:1335–1342, 2008.
Winter WE 3rd, Maxwell GL, Tian C, et al: Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 94:495–501, 2004.
Acknowledgments: The authors would like to thank Dr. Xipeng Wang, Dr. Hye-Sook Chon, Dr. Xi Cheng, and Lora Lothringer for their assistance.
